Holen Sie sich die Stockscreener-App
15.02
3.75%
-0.585
Schlusskurs vom Vortag:
$15.60
Offen:
$15.6
24-Stunden-Volumen:
1.52M
Relative Volume:
1.41
Marktkapitalisierung:
$1.07B
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-3.1744
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
-4.42%
1M Leistung:
+5.67%
6M Leistung:
+60.25%
1J Leistung:
+116.04%
1-Tages-Spanne:
$14.77
$15.74
1-Wochen-Bereich:
$14.77
$18.09
52-Wochen-Spanne:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
15.02 | 1.11B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - ulpravda.ru
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - MarketScreener
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - ulpravda.ru
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Phathom Pharmaceuticals Announces Pricing of $130 Million - GlobeNewswire
Phathom Pharmaceuticals, Inc.Common Stock (NQ: PHAT - FinancialContent
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView — Track All Markets
Phathom Pharmaceuticals stock falls on planned public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals drops after announcing planned equity raise - TradingView — Track All Markets
PHAT Forecasts Profitable Operations by 2026 - GuruFocus
Phathom Pharmaceuticals stock falls on planned public offering - Investing.com
Phathom Pharmaceuticals files for mixed shelf offering size not disclosedSEC filing - MarketScreener
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million - MarketScreener
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Drugmaker developing GI treatments plans new stock and warrant sale - Stock Titan
Phathom Pharmaceuticals: Speculative Biotech Name Rides A Fresh Wave Of Volatility - AD HOC NEWS
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Phathom Pharmaceuticals grants RSUs and options to CEO Steven Basta | PHAT SEC FilingForm 4 - Stock Titan
(PHAT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: What makes Phathom Pharmaceuticals Inc stock attractive to growth funds2025 Big Picture & Real-Time Buy Signal Alerts - moha.gov.vn
Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week HighHere's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Is Expected To Breakeven In The Near Future - Yahoo Finance
Phathom Pharmaceuticals stock hits 52-week high at $17.87 By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals stock hits 52-week high at $17.87 - Investing.com India
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Is Phathom Pharmaceuticals Inc. stock oversold or undervaluedTrade Entry Summary & Community Consensus Picks - Улправда
Bull Run: Why Phathom Pharmaceuticals Inc. stock is favored by pension funds2025 Winners & Losers & Weekly Stock Performance Updates - Улправда
Is Phathom Pharmaceuticals Inc. stock cheap at current valuationWeekly Profit Report & Daily Profit Maximizing Tips - DonanımHaber
Will Phathom Pharmaceuticals Inc. stock benefit from AI adoptionBear Alert & Verified Momentum Watchlists - Улправда
Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Update Summary & Expert Curated Trade Setup Alerts - Улправда
Market Moves: Is Phathom Pharmaceuticals Inc. stock oversold or undervalued2025 Winners & Losers & Consistent Income Trade Ideas - Улправда
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):